Thanks for a great night at the #GGBAwards. A big shout out to all the entries for this year’s #CSR Initiative of the Year award. It’s so encouraging to see all the great work the Generics sector is doing to support people in need. Generics bulletin Dave Wallace, Generics Bulletin executive editor

In this interview, CEO Michael Goettler provides an update on the progress made by Viatris in its first year, also previewing the detailed strategy that will be unveiled at the firm’s upcoming investor day and underlining the importance of biosimilars and complex generics.

With the Big Give, International Health Partners is raising money to get vital medicine to people who need it. For every £1 donated, IHP can send £20 worth of medicine. bit.ly/32MXgQI …nerics.pharmaintelligence.informa.com/GB151454/IHP-W…

With the first approved rival to Lucentis in both the EU and US, Samsung Bioepis is laying the groundwork for biosimilars to break into ophthalmology ahead of launching its Byooviz version of ranibizumab, explains vice-president of commercial strategy Josh Lee.

Alvotech founder and chairman Róbert Wessman tells Generics Bulletin how the firm plans to move forward following recently-revealed plans for a SPAC merger that will provide fresh impetus for the biosimilars specialist with an injection of almost $500m in funding. Alvotech

This is the first part of an exclusive two-part interview with David Wallace at Generics bulletin, where I talk about Alvotech’s plans to move forward following the SPAC merger, partnerships, and strategy on our biosimilars journey. bit.ly/3rhti0V

In the second part of an exclusive two-part interview with Generics Bulletin, Alvotech founder and chairman Róbert Wessman sets out the firm’s expectations for its rival to Humira as it continues to battle AbbVie in US litigation over its higher-strength adalimumab biosimilar.

Biosimilars Forum executive director Juliana Reed discusses the Forum's priorities and leadership in the #biosimilars industry in an interview with Dave Wallace, Generics Bulletin executive editor Generics bulletin Read more here: …nerics.pharmaintelligence.informa.com/GB151651/Reed-…

In an exclusive interview with Generics Bulletin, the Biosimilars Forum Forum’s executive director Julie Reed sets out the group’s priorities and explains how its diverse membership is helping to position it as a leading voice for the US biosimilars industry.

In this @Pharma_Intell interview, #AAMBoard Vice Chair Christine Baeder (Senior Vice President, Chief Operating Officer for US Generics Teva Pharmaceuticals) explores the challenges and opportunities of #ComplexGenerics. Read: …nerics.pharmaintelligence.informa.com/GB151308/Tevas…

With key milestones on the horizon for US biosimilars in 2022 and 2023, Cardinal Health VP of biosimilars Sonia Oskouei explains how the industry can best position itself to take advantage of upcoming opportunities, including potentially a global leadership role in ophthalmology.

A major biosimilars deal between Biocon and Viatris to kick off this week:

Sonia Oskouei, Cardinal Health VP of biosimilars, talks about how real-world evidence and education can build confidence in biosimilars, as well as the ongoing struggle against misinformation and need for clarity over concepts such as interchangeability and unbranded biologics.

In this two-part interview, I talk to Hikma CEO Siggi Olafsson about how Hikma expects to maintain its deal-making momentum, future plans for US biosimilars, and how it is positioned to deal with pricing pressures and increased competition on some of its key generics.

In an exclusive two-part interview, Samsung Bioepis development division leader Kyung-ah Kim and Biogen global head of biosimilars Ian Henshaw discuss how the firms are aiming to capitalize on their launch of the world’s first Lucentis biosimilar, Byooviz, in the US.

At an eventful time for US biosimilars, a fresh wave of players entering the market is expected to both increase competition and broaden access, says AmerisourceBergen’s (AB (Formerly AmerisourceBergen)’s) senior vice president for global emerging therapies and channel strategy, Beth McMahon.

In this exclusive two-part interview, Amgen 🧪🔬🧬's Chad Pettit, Amgen Biosimilars commercial lead, talks to Generics bulletin about the firm’s “unique perspective” on biosimilars, including how competition to Humira is expected to signal a major shift in the US biosimilars landscape.

This week Generics Bulletin has published its annual Top 50 ranking by turnover of the world's leading generics and biosimilars players. You can read the first of our four articles here:

Shortlist Unveiled For GGB Awards bit.ly/3BQWMXF

Amgen Delivers On Launch Of First US Humira Rival – At A 55% Discount bit.ly/3DusTxT